Consideration is set at $31.50 per Catalyst share in cash, implying an equity value above $4.1 billion and a 21% premium to ...
Madrigal Pharmaceuticals entered an exclusive global license agreement with Arrowhead Pharmaceuticals for ARO-PNPLA3, a ...
Pharmaceutical Executive: What elements is the conversation about bringing pharma manufacturing home missing? Charlie Lyon: ...
In March of this year, the API Innovation Center released its whitepaper titled, “From Fragility to Resilience: Aligning ...
Pharmaceutical Executive spoke with Aradigm Health CEO Will Shrank at the Asembia ASX26 Summit in Las Vegas. During the conversation, he explained the issues the payers face with cell & gene therapies ...
Ultimately, making RWE actionable means shortening the gap between insight and application. When data is reliable, complete, and easy to use, it can support better decisions, faster adoption of new ...
FDA authorization supports a mid-stage clinical evaluation of CK0802 in steroid-refractory GVHD, where steroid nonresponse is ...
UCB enters agreement to acquire Candid Therapeutics in a deal worth up to $2.2 billion, adding BCMA-targeting T-cell engager ...
Aradigm Health CEO Will Shrank discusses the shift in value-based care models for cell and gene therapies. While advances in ...
In today's Pharmaceutical Executive Daily, Cellenkos announces FDA clearance of its investigational new drug application for ...
BioNTech reports its first quarter finical results, including losses and declining Covid-19 revenue as the company ...
In today's Pharmaceutical Executive Daily, UCB announces a definitive agreement to acquire Candid Therapeutics for up to $2.2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results